Successful Early Testing of Concussion Therapy Drives

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
223
Successful Early Testing of Concussion Therapy Drives Optimism for Odyssey Health, Inc. (ODYY) as Next-stage Trials are Readied

- Medical technology innovator Odyssey Health Inc. is using clinical tests to establish the safety of a therapy designed to treat concussion injuries in its earliest moments
- The company is enthused by results from the early-stage testing and is preparing to design a Phase II/III trial that will target efficacy results in volunteer subjects, focusing particularly on members of the military
- Odyssey’s technology combines a synthetic medication with a specially designed application device that helps the medication cross the blood-brain barrier for immediate responsiveness following a mild traumatic brain injury (“mTBI”)
- Medication for concussion treatment remains an unmet need and Odyssey is aiming to be a first-mover in the healthcare sector

The National Council on Aging sponsors its Falls Prevention Week timed, not ironically, during the fall of each year, using its national health campaign to combat the leading cause of fatal and non-fatal injuries among older adults.

One message of the council’s awareness campaign is the importance of recognizing that after an old person is helped back up, the fall victim may be able to resume walking, but there is still a significant risk of worsening effects from a concussion-related head injury (https://nnw.fm/hNN8B ).

While the potential harm of concussion injuries in youth sports and among professional athletes is gaining an increasing measure of attention, concussions in elderly fall patients is also a prominent concern, and active military personnel also continue evaluating potential new treatments for concussion injuries sustained on duty.

Medical device innovator and biopharmaceutical product developer Odyssey Health (OTC: ODYY) is working to address unmet needs in concussion therapy, to help patients beyond the standard of care for pain management, rest, and monitoring.

A proprietary device and synthetic medication combination developed by Odyssey Health is being tested for safety related to treating concussion patients in the initial moments after a mild injury, successfully completing all three cohorts in the company’s Phase I Single Ascending Dosing (“SAD”) clinical trial recently and advancing to a Multiple Ascending Dosing (“MAD”) stage in which volunteers will be treated once daily for five straight days.

“We have a very unique new chemical entity intended to treat mild traumatic brain injury — the acute phase of a concussion,” CEO Michael Redmond said during an interview with The RedChip Money Report(R) last month. “It’s a small device. It essentially goes and delivers a powderized drug through the upper chambers of the nasal cavity. The drug crosses the blood-brain barrier within five minutes. It spreads out throughout the brain within 30 minutes and reverses the effects of a concussion” (https://nnw.fm/g4bvg ).

The SAD and MAD clinical trials work with healthy human volunteers to establish the safety of Odyssey Health’s technology, which previously completed preclinical lab animal testing successfully and is expected to advance to a Phase II/III design that will determine the efficacy of the company’s PRV-002 technology for concussed patients.

Phase II trial sites are already being identified and the study’s design is being created, working with military board advisers while company officials report their early efforts to the FDA.

“We are actively identifying and assisting with Phase II military trial site setup,” Major General (Ret.) Jim Linder, the former chief of staff for the U.S. Special Operations Command, stated in a July 12 news release about Odyssey’s progress (https://nnw.fm/BtLXY ). “We need a treatment to prevent the long-term consequences of concussion as far too many of our Service Members are retiring with TBI disorders that lessen their quality of life.”

A significant target of the therapy involves getting the drug across the blood-brain barrier to directly deal with the central nervous system consequences of a head injury.

“I am especially excited to see the overall low levels of PRV-002 in the blood supporting the hypothesis that more drug is getting to the brain itself when administered with the intranasal device”, Safety Review Committee member Dallas Hack, MD, stated after analyzing the SAD trial. “If this turns out to be the case, not only can the targeted effects of the drug be more efficacious, the drug will likely have less potential side effects.”

For more information, visit the company’s website at www.OdysseyHealthInc.com.

NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://nnw.fm/ODYY

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Odyssey Group Intl Inc (ODYY) Stock Research Links

ODYY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 0

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 110

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
HONOR Leads in China, Eyes Middle East Market

Updated Category News Views 23

A Force to be Reckoned With Talk about making waves—HONOR's got the bragging rights now. Sitting pretty at the top among Android smartphone brands in China ain't no small feat. We're looking at a snazzy 12.04% market share for October 2026, all thanks to selling a cool 2.573 million units. The kicker? This ain't even their full potential. They're hustling hard in the...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 258

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 102

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Net Zero Efforts to Cost Europe €60B Annually by 2050

Updated Category News Views 38

Hefty Prices Loom Over Net Zero Commitments Well, strap in for a wallet buster, folks. Europe's largest players are staring down the barrel of a colossal €60 billion annual bill to clean up their carbon mess by 2050. That's the ticker in Senken's latest report, 'Pace of Change 2026.' Talks like these remind me there's no such thing as a free lunch, especially when...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 63

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
NestWorks' C500: Shaking Up CNC at Formnext 2026

Updated Category News Views 41

NestWorks C500: A Game Changer for Makers Folks, gather 'round, because NestWorks is turning heads with their C500 desktop CNC machine. As it lands firmly on TIME’s Best Inventions of 2026 list, this ain't just another gadget adorning a workshop—all eyes are on it at Formnext 2026. From November 17–20, Frankfurt is the stage where NestWorks plans to showcase how...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 106

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading

Top 5 Most Recently Viewed Articles

Flow Beverage Welcomes José Bautista as Advisor and Announces Fundraising Progress

Updated Category News Views 336

Flow Beverage Corp. Welcomes José Bautista as Strategic Advisor Flow Beverage Corp. (TSX:FLOW; OTCQX:FLWBF) has recently made a significant move by bringing on board José Bautista as a Strategic Advisor. This addition is seen as a promising enhancement to the company's team, aligning with its dedication to excellence and innovation in the beverage sector. Background of...

Continue Reading
Milan Laser Hair Removal Marks a Significant 400 Clinic Milestone

Updated Category News Views 207

Milan Laser Hair Removal Reaches 400 Clinics Nationwide The leading provider in laser hair removal achieves a remarkable milestone with nationwide expansion efforts. Milan Laser Hair Removal, the hallmark of laser hair removal in the nation, proudly celebrates the grand opening of its 400th clinic, symbolizing a major advancement in its rapid expansion across the country....

Continue Reading
Global Vertical Roller Mill Market Expands to USD 1.04 Billion

Updated Category News Views 215

Understanding the Global Vertical Roller Mill Market The Vertical Roller Mill (VRM) market is anticipated to experience significant growth in the coming years. Currently valued at approximately USD 608.5 million in 2024, projections indicate that it will reach USD 1,041.2 million by 2033, achieving a compound annual growth rate (CAGR) of 6.1%. This increase is largely due...

Continue Reading
Pulsar Helium Provides Insights on Progress at Topaz Project

Updated Category News Views 313

Pulsar Helium Develops Well-Testing Strategy at Topaz Project Pulsar Helium Inc. (AIM: PLSR, TSXV: PLSR, OTCQB: PSRHF), a leading helium development company, has recently provided valuable updates regarding its well-testing activities at the Topaz project, located in Minnesota. This momentous phase in the project holistically aims to assess helium extraction capabilities...

Continue Reading
Trade Disclosures: Treatt plc's Key Operations Analyzed

Updated Category News Views 178

Understanding Recent Trade Disclosures by Treatt plc Treatt plc, a company known for its expertise in manufacturing and distributing essential oils and flavouring agents, operates in a competitive sector where trade disclosures play a crucial role in maintaining transparency and building investor trust. As we delve into the recent disclosures made by Treatt plc, we'll...

Continue Reading